Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

BACKGROUND: Prognosis of KRAS wild-type and mutant metastatic colorectal cancer (MCRC) patients (pts) treated with bevacizumab (BEV)-containing chemotherapy is not significantly different. Since specific KRAS mutations confer different aggressive behaviors, the prognostic role of prevalent KRAS muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, Lamy, Aude, Frébourg, Thierry, Sabourin, Jean Christophe, Tosi, Mario, Alesse, Edoardo, Ficorella, Corrado, Ricevuto, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635869/
https://www.ncbi.nlm.nih.gov/pubmed/23497191
http://dx.doi.org/10.1186/1741-7015-11-59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635869/
https://www.ncbi.nlm.nih.gov/pubmed/23497191
http://dx.doi.org/10.1186/1741-7015-11-59

Ejemplares similares